Ubiquinol

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: energy heart longevity

Research Overview

Across the abstracts, ubiquinol (the reduced form of coenzyme Q10) is most frequently studied in the context of mitochondrial biology and redox control. Mechanistically oriented work emphasizes ubiquinol’s central role in the electron transport chain (as part of the ubiquinone/ubiquinol pool) and in limiting lipid peroxidation, including within emerging ferroptosis-regulatory networks. Multiple lines of research connect ubiquinol homeostasis to ferroptosis suppression pathways (e.g., NAD(P)H–FSP1–ubiquinone/ubiquinol and related mitochondrial enzymes), and to broader mitochondrial quality-control and stress-response programs (e.g., AMPK signaling, mitophagy, and mitochondrial injury during ischemia/reperfusion). In parallel, applied studies and reviews address CoQ10/ubiquinol supplementation in settings characterized by oxidative stress and high mitochondrial demand, including exercise physiology and reproductive aging models (oocytes), with some clinical/preclinical synthesis work summarizing the last decade of CoQ research.

The strongest evidence supported by these abstracts is that ubiquinol is a key endogenous antioxidant and electron carrier whose availability and reduction state influence susceptibility to oxidative damage and lipid peroxidation, including ferroptotic cell death. In cancer-focused mechanistic studies, manipulating mitochondrial complex I and AMPK signaling alters ubiquinol levels and ferroptosis sensitivity, with particular relevance to genetic contexts such as LKB1 deficiency and potential synergy with radiotherapy. In human exercise studies, short-term ubiquinol supplementation (e.g., 200 mg/day for one month in a double-blind cross-over design) consistently increases circulating CoQ status and attenuates biochemical and cellular oxidative stress signals after intense exercise, but does not clearly translate into improved performance outcomes. Collectively, the evidence base is strongest for biochemical/mitochondrial effects (redox markers, CoQ pool dynamics, and cell-death pathway modulation) rather than for robust, consistent improvements in functional clinical endpoints.

Key gaps include (i) clearer causal links between changing ubiquinol status and clinically meaningful outcomes across diseases where ferroptosis and mitochondrial dysfunction are implicated (e.g., ischemia/reperfusion injury, neurodegeneration, liver injury), (ii) better definition of dose–response relationships, tissue targeting, and pharmacokinetics/pharmacodynamics for ubiquinol supplementation versus modulation of endogenous CoQ redox cycling, and (iii) more rigorous, adequately powered clinical trials with standardized endpoints beyond oxidative stress biomarkers (e.g., recovery, organ function, morbidity). Mechanistically, additional work is needed to integrate compartment-specific ubiquinol pools (mitochondrial vs. extramitochondrial membranes), interactions with AMPK/mitophagy pathways, and epigenetic regulation of ferroptosis into unified models that can guide therapeutic strategies and patient stratification.

1. What conditions has Ubiquinol been studied for?

  • Exercise-induced oxidative stress / recovery in athletes: A double-blind cross-over study in young male athletes tested ubiquinol 200 mg/day for 1 month and measured oxidative stress and muscle damage markers after intense exercise.

  • Type 2 diabetes (glycemic control and antioxidant status): A randomized, double-blind, placebo-controlled trial tested a “liquid ubiquinol” supplement at 100 mg/day for 12 weeks in adults with type 2 diabetes.

  • Ischemic stroke / neuroprotection (primarily CoQ10, with relevance to ubiquinol): A review discusses CoQ10’s neuroprotective mechanisms in ischemic stroke and notes that reduced CoQ10 (ubiquinol) levels are deficient in the brain; evidence cited includes in vitro, in vivo, and clinical observations (not necessarily ubiquinol-only trials).

  • Neurologic disorders broadly (mostly CoQ10): A review summarizes potential roles of CoQ10 in migraine, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ALS, and Friedreich’s ataxia (the abstracts do not clearly specify ubiquinol vs ubiquinone in these conditions).

  • Reproductive/aging biology (preclinical): Ubiquinol-10 was studied in porcine oocytes during postovulatory aging (cell/animal model context).

  • Ferroptosis-related biology (mechanistic, not supplementation trials): Multiple abstracts discuss ubiquinol/ubiquinone systems (e.g., FSP1 reducing ubiquinone to ubiquinol; dihydroorotate dehydrogenase/ubiquinol pathway) as regulators of ferroptosis, relevant to cancer therapy and CNS injury mechanisms.

  • Alcohol-related liver injury (mechanistic mitochondrial pathway): One abstract links AMPK, UQCRC2 (ubiquinol-cytochrome c reductase core protein 2), mitophagy, and attenuation of alcohol-induced liver injury (this is not a ubiquinol supplementation study, but involves ubiquinol-related mitochondrial complex biology).

  • Cardiac ischemia/reperfusion injury (mitochondrial injury focus): A review focuses on mitochondrial mechanisms in myocardial ischemia/reperfusion injury and therapeutic strategies targeting mitochondria; it does not specifically test ubiquinol supplementation but is mechanistically relevant to CoQ/mitochondrial function.

2. Does it work in treating those conditions? Summarize the evidence.

  • Type 2 diabetes: modest supportive evidence (one RCT). In a 12-week randomized, double-blind, placebo-controlled trial (100 mg/day liquid ubiquinol), the ubiquinol group had a statistically significant reduction in HbA1c (P=0.03) and improved antioxidant enzyme activities (catalase P<0.01; glutathione peroxidase P=0.03). Lipids largely did not change, but HDL fell in the placebo group while being maintained in the ubiquinol group. This supports a potential adjunctive benefit for glycemic control and antioxidant status, but the abstract does not indicate large clinical endpoints (e.g., complications), and the sample size was modest (n=50).

  • Exercise-induced oxidative stress: improves antioxidant markers, not performance or muscle damage. In the athlete cross-over study (200 mg/day for 1 month), intense exercise caused rapid CoQ depletion; ubiquinol supplementation minimized exercise-induced depletion and enhanced plasma/cellular antioxidant levels. However, it did not improve physical performance indices or markers of muscle damage (e.g., CK, myoglobin), indicating biochemical effects without clear functional benefit in that protocol.

  • Ischemic stroke / neurologic disease: suggestive but largely indirect for ubiquinol. Reviews describe CoQ10 as neuroprotective after ischemic stroke via anti-oxidative stress, anti-nitrosative stress, anti-inflammation, and anti-cell death mechanisms, drawing on in vitro, in vivo, and “clinical observations.” However, the abstracts provided do not establish that ubiquinol supplementation specifically has proven clinical efficacy in stroke outcomes; the evidence appears mixed in type and not clearly limited to randomized clinical trials.

  • Ferroptosis/cancer/CNS injury mechanisms: mechanistic evidence, not clinical supplementation evidence. Several abstracts indicate that ubiquinol-related pathways (e.g., FSP1 reducing ubiquinone to ubiquinol; ETC complex I effects on ubiquinol levels and AMPK activation) can suppress or modulate ferroptosis. One abstract reports that complex I inhibition can sensitize LKB1-deficient tumors to GPX4-inhibition-induced ferroptosis and synergize with radiotherapy in mouse models. These findings are important biologically but do not show that taking ubiquinol as a supplement treats cancer or CNS disease; in some contexts, increasing ferroptosis is a desired anti-cancer strategy, so antioxidant/ubiquinol biology could theoretically cut both ways depending on context.

  • Oocyte aging (porcine): preclinical only. The porcine oocyte study indicates investigation of ubiquinol-10 during postovulatory aging; without outcomes in the excerpt, it cannot be concluded clinically effective for fertility or reproductive aging in humans.

3. What health benefits does it have?

  • Improves antioxidant defenses in certain settings: In type 2 diabetes, ubiquinol increased catalase and glutathione peroxidase activities after 12 weeks. In athletes, supplementation enhanced plasma/cellular antioxidant levels and reduced exercise-associated CoQ depletion.

  • May modestly improve glycemic control in type 2 diabetes (adjunctive): The diabetes RCT reported a statistically significant reduction in HbA1c and a lower anti-glycemic medication effect score versus placebo, suggesting potential supportive metabolic benefit.

  • Mitochondrial bioenergetic support (biological plausibility): Multiple abstracts reiterate CoQ’s central role as a lipid electron transporter in the mitochondrial electron transport chain and ubiquinol as the reduced, antioxidant-active form. This supports plausibility for benefits in conditions involving mitochondrial dysfunction and oxidative stress, though clinical proof varies by condition.

  • Cell-protective effects in models: Ubiquinol-10 is described as protecting mammalian cells from oxidative damage and enhancing mitochondrial activity (and was investigated in oocyte aging). Mechanistic ferroptosis literature also positions ubiquinol as part of anti-lipid-peroxidation defense systems (e.g., FSP1/ubiquinone/ubiquinol axis), which may be relevant to tissue protection in oxidative injury contexts.

4. Does it have any downsides or side effects?

  • Limited benefit on some meaningful outcomes: In the athlete trial, ubiquinol did not improve physical performance or muscle damage markers despite improving antioxidant measures—so a key “downside” is that biochemical improvements may not translate into functional or clinical improvements in certain contexts.

  • Potential theoretical concern in cancer contexts (mechanism-dependent): Several abstracts emphasize ferroptosis as a tumor-suppression mechanism and describe ubiquinol-generating systems (e.g., FSP1 reducing ubiquinone to ubiquinol) as ferroptosis-suppressive. In theory, strong ferroptosis suppression could be undesirable in some oncology settings where inducing ferroptosis is therapeutic. The provided abstracts do not show that oral ubiquinol supplementation worsens cancer outcomes, but they do support a biologically plausible context-dependent risk that warrants caution and clinician input for patients undergoing ferroptosis-inducing therapies.

  • Adverse events not described in the provided abstracts: The diabetes RCT and athlete study abstracts provided do not report specific side effects or tolerability issues. Therefore, no evidence-based side-effect profile can be concluded from these excerpts alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • LKB1 (STK11) / AMPK pathway status may change how ubiquinol-related biology affects ferroptosis (preclinical): One abstract reports that complex I inhibition sensitized LKB1-deficient tumors to GPX4-inhibition-induced ferroptosis and synergized with radiotherapy in mouse models, while AMPK activation can be ferroptosis-suppressive. This indicates that genetic alterations affecting the LKB1–AMPK axis can strongly influence ferroptosis regulation in response to mitochondrial/ubiquinol changes. However, this is not evidence that ubiquinol supplementation is beneficial or harmful in LKB1 variant carriers; it is mechanistic oncology evidence.

  • No direct supplement pharmacogenomic trials in the provided abstracts: The abstracts do not report human studies stratifying ubiquinol response by genotype (e.g., CoQ biosynthesis genes, FSP1/AIFM2 variants, ETC complex genes). Therefore, any pharmacogenomic conclusions about who should or should not take ubiquinol remain unproven based on the provided material.

References

  1. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.
    Chao Mao, Xiaoguang Liu, Yilei Zhang, Guang Lei, Yuelong Yan, Hyemin Lee, Pranavi Koppula, Shiqi Wu, Li Zhuang, Bingliang Fang, Masha V Poyurovsky, Kellen Olszewski, Boyi Gan (2021) - Nature
  2. Mitochondrial Dysfunction and Myocardial Ischemia-Reperfusion: Implications for Novel Therapies.
    Edward J Lesnefsky, Qun Chen, Bernard Tandler, Charles L Hoppel (2017) - Annual review of pharmacology and toxicology
  3. Role of Coenzyme Q
    Ilenia Cirilli, Elisabetta Damiani, Phiwayinkosi Vusi Dludla, Iain Hargreaves, Fabio Marcheggiani, Lauren Elizabeth Millichap, Patrick Orlando, Sonia Silvestri, Luca Tiano (2021) - Antioxidants (Basel, Switzerland)
  4. Metabolic Targets of Coenzyme Q10 in Mitochondria.
    Agustín Hidalgo-Gutiérrez, Pilar González-García, María Elena Díaz-Casado, Eliana Barriocanal-Casado, Sergio López-Herrador, Catarina M Quinzii, Luis C López (2021) - Antioxidants (Basel, Switzerland)
  5. AMPK protects against alcohol-induced liver injury through UQCRC2 to up-regulate mitophagy.
    Xinyi Lu, Wenting Xuan, Juanjuan Li, Hongwei Yao, Cheng Huang, Jun Li (2021) - Autophagy
  6. An ETFDH-driven metabolon supports OXPHOS efficiency in skeletal muscle by regulating coenzyme Q homeostasis.
    Juan Cruz Herrero Martín, Beñat Salegi Ansa, Gerardo Álvarez-Rivera, Sonia Domínguez-Zorita, Pilar Rodríguez-Pombo, Belén Pérez, Enrique Calvo, Alberto Paradela, David G Miguez, Alejandro Cifuentes, José M Cuezva, Laura Formentini (2024) - Nature metabolism
  7. Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers.
    Chao Mao, Guang Lei, Amber Horbath, Min Wang, Zhengze Lu, Yuelong Yan, Xiaoguang Liu, Lavanya Kondiparthi, Xiong Chen, Jun Cheng, Qidong Li, Zhihao Xu, Li Zhuang, Bingliang Fang, Joseph R Marszalek, Masha V Poyurovsky, Kellen Olszewski, Boyi Gan (2024) - Molecular cell
  8. Coenzyme Q
    Alma Martelli, Lara Testai, Alessandro Colletti, Arrigo F G Cicero (2020) - Antioxidants (Basel, Switzerland)
  9. Rhodoquinone carries electrons in the mammalian electron transport chain.
    Jonathan Valeros, Madison Jerome, Tenzin Tseyang, Paula Vo, Thang Do, Diana Fajardo Palomino, Nils Grotehans, Manisha Kunala, Alexandra E Jerrett, Nicolai R Hathiramani, Michael Mireku, Rayna Y Magesh, Batuhan Yenilmez, Paul C Rosen, Jessica L Mann, Jacob W Myers, Tenzin Kunchok, Tanner L Manning, Lily N Boercker, Paige E Carr, Muhammad Bin Munim, Caroline A Lewis, David M Sabatini, Mark Kelly, Jun Xie, Michael P Czech, Guangping Gao, Jennifer N Shepherd, Amy K Walker, Hahn Kim, Emma V Watson, Jessica B Spinelli (2025) - Cell
  10. Coenzyme Q
    Francisco M Gutierrez-Mariscal, Silvia de la Cruz-Ares, Jose D Torres-Peña, Juan F Alcalá-Diaz, Elena M Yubero-Serrano, José López-Miranda (2021) - Antioxidants (Basel, Switzerland)
  11. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.
    André Campaniço, Rui Moreira, Francisca Lopes (2018) - European journal of medicinal chemistry
  12. Epigenetic Regulation of Ferroptosis in Central Nervous System Diseases.
    Ting Lan, Ting Ting Sun, Chao Wei, Tian Cheng, Fei Yang, Jian-Nan Zhang, Qian Li (2023) - Molecular neurobiology
  13. Unleashing Ferroptosis in Human Cancers: Targeting Ferroptosis Suppressor Protein 1 for Overcoming Therapy Resistance.
    Jaewang Lee, Jong-Lyel Roh (2023) - Antioxidants (Basel, Switzerland)
  14. Ubiquinol-10 delays postovulatory oocyte aging by improving mitochondrial renewal in pigs.
    Ying-Jie Niu, Wenjun Zhou, Zheng-Wen Nie, Dongjie Zhou, Yong-Nan Xu, Sun A Ock, Chang-Guo Yan, Xiang-Shun Cui (2020) - Aging
  15. Coenzyme Q
    Franchek Drobnic, Mª Antonia Lizarraga, Alberto Caballero-García, Alfredo Cordova (2022) - Nutrients
  16. Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes.
    Patrick Orlando, Sonia Silvestri, Roberta Galeazzi, Roberto Antonicelli, Fabio Marcheggiani, Ilenia Cirilli, Tiziana Bacchetti, Luca Tiano (2018) - Redox report : communications in free radical research
  17. Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases.
    Alireza Ebrahimi, Amirhossein Kamyab, Sahar Hosseini, Sedigheh Ebrahimi, Soheil Ashkani-Esfahani (2023) - Biochemistry research international
  18. Therapeutic Effects of Coenzyme Q10 in the Treatment of Ischemic Stroke.
    Zhilei Jia, Xiaoya Yu, Xu Wang, Jinhua Li (2024) - Current nutrition reports
  19. Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial.
    Chi-Hua Yen, Ying-Ju Chu, Bor-Jen Lee, Yi-Chin Lin, Ping-Ting Lin (2018) - The British journal of nutrition
  20. Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure.
    Mark F McCarty (2021) - International journal of molecular sciences


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!